Personalized pharmacotherapy for Type 2 diabetes mellitus

被引：9
作者：
Sathananthan, Airani [1 ]
Vella, Adrian [1 ]
机构：
[1] Mayo Clin, Div Endocrinol Diabet & Metab, Dept Med, Rochester, MN 55905 USA
来源：
PERSONALIZED MEDICINE | 2009年 / 6卷 / 04期
关键词：
OCT; 1; pharmacogenetics; sulfonylureas; TCF7L2; Type 2 diabetes mellitus; DIPEPTIDYL PEPTIDASE-4 INHIBITORS; INSULIN-SECRETION; SECONDARY FAILURE; INCREASED RISK; TCF7L2; GENE; VARIANT; SULFONYLUREA; THERAPY; POLYMORPHISMS; PIOGLITAZONE;
D O I：
10.2217/PME.09.3
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Genome-wide linkage and association studies have been applied to Type 2 diabetes in order to discover common genetic variation that contributes to disease risk. While there has been progress in understanding how genetic variation predisposes to diabetes, there is less of an understanding of how genetics can alter drug response. The hope is that in the future, pharmacogenetics can help guide the treatment of diabetes, thereby improving control while minimizing side effects in a large group of patients.
引用
收藏
页码：417 / 422
页数：6
相关论文
共 36 条
  • [1] Dipeptidyl peptidase-4 inhibitors -: Clinical data and clinical implications
    Ahren, Bo
    [J]. DIABETES CARE, 2007, 30 (06) : 1344 - 1350
  • [2] *AM DIAB ASS, 2009, DIABETES CARE S1, V32, pS31
  • [3] Efficacy and safety of incretin therapy in type 2 diabetes - Systematic review and meta-analysis
    Amori, Renee E.
    Lau, Joseph
    Pittas, Anastassios G.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 298 (02): : 194 - 206
  • [4] Barr C C, 2001, Surv Ophthalmol, V45, P459, DOI 10.1016/S0039-6257(01)00187-4
  • [5] A human glucagon-like peptide-1 receptor polymorphism results in reduced agonist responsiveness
    Beinborn, M
    Worrall, CI
    McBride, EW
    Kopin, AS
    [J]. REGULATORY PEPTIDES, 2005, 130 (1-2) : 1 - 6
  • [6] Analysis of the relationship between the pro12Ala variant in the PPAR-γ2 gene and the response rate to therapy with pioglitazone in patients with type 2 diabetes
    Blüher, M
    Lübben, GR
    Paschke, R
    [J]. DIABETES CARE, 2003, 26 (03) : 825 - 831
  • [7] Development of glucagon-like peptide-1-based pharmaceuticals as therapeutic agents for the treatment of diabetes
    Drucker, DJ
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2001, 7 (14) : 1399 - 1412
  • [8] Ferrannini E, 1998, ENDOCR REV, V19, P477, DOI 10.1210/er.19.4.477
  • [9] Type 2 diabetes-associated missense polymorphisms KCNJ11 E23K and ABCC8 A1369S influence progression to diabetes and response to interventions in the diabetes prevention program
    Florez, Jose C.
    Jablonski, Kathleen A.
    Kahn, Steven E.
    Franks, Paul W.
    Dabelea, Dana
    Hamman, Richard F.
    Knowler, William C.
    Nathan, David M.
    Altshuler, David
    [J]. DIABETES, 2007, 56 (02) : 531 - 536
  • [10] TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program
    Florez, Jose C.
    Jablonski, Kathleen A.
    Bayley, Nick
    Pollin, Toni I.
    de Bakker, Paul I. W.
    Shuldiner, Alan R.
    Knowler, William C.
    Nathan, David M.
    Altshuler, David
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (03) : 241 - 250
1234